Sofia Fund News & Blog

Getting to Success: Advice from a Tech Entrepreneur Turned Angel

First blog in a series by Lisa Crump, founder of Cairn Ventures and Managing Partner, Sofia Fund. View Part II here. View Part III here.

As co-founder of Stratasys, Inc., a pioneering 3D printing technology company, I worked with a team of remarkable, risk-taking contributors – talented employees and managers, skilled board members and advisors, early investors, far-sighted customers, supportive vendors and a visionary co-founder.…

Joylux Named One of The Top Three Most Innovative Companies by Angel Capital Association

Joylux to be honored at the Angel Capital Association’s 2019 Summit as a top-three finalist for the prestigious Luis Villalobos Award

Seattle, WA, March 25, 2019 — Joylux, a leading FemTech company using high-tech solutions to improve vaginal health for postpartum and menopausal women, has been named one of the top three most ingenious and innovative companies funded by Angel Capital Association (ACA) members, a membership of 14,000+ accredited angel investors.…

Thrive Global Recognizes Sofia Portfolio Company Oculogica

Oculogica is highlighted in the Community section under the headline The Future of Healthcare “Tracking a person’s eye movements to diagnose brain injuries” with Dr. Uzma Samadani of Oculogica. Read the entire article here:

https://thriveglobal.com/stories/the-future-of-healthcare-tracking-a-persons-eye-movements-to-diagnose-brain-injuries-with-dr-uzma-samadani-of-oculogica/

Sofia Fund Invests in Landit

Minneapolis, MN, February 28, 2019 — Sofia Fund, a leading angel investment group focused on high-growth, women-led companies, today announced its most recent investment in Landit, a technology platform that increases the success and engagement of women and diverse groups in the workplace.…

Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™

Pittsburgh, PA, February 21, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders, today announced the issuance by the European Patent Office of a composition of matter patent covering Elayta™, Cognition’s lead clinical stage compound in development for individuals with Alzheimer’s disease. …

Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™

Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement

Pittsburgh, PA, February 19, 2019 (GLOBE NEWSWIRE)Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, announced today the publication of clinical data from the Company’s Phase 1 trial of Elayta™ (CT1812) in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.…